acalabrutinib
astrazeneca
['acalabrutinib', 'lymsm', 'cll']
patients 80 years+ and/or considered frail who received #acalabrutinib for #cll experienced toxicities consistent with prior trials. #eha2023 #lymsm 
Oncology news and insights from leading researchers and cancer centers.